The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

Category: Pharma & Human Health

Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
Editor's Choice

Targeting the ileo-colonic region: Innovative solutions for sensitive APIs

AUG 21, 2025
SNIPR BIOME Raises EUR 35 Million Series B Financing
Finance

SNIPR BIOME Raises EUR 35 Million Series B Financing

AUG 7, 2025
Experts publish first global framework for quantifying postbiotics
Biotics and Supplements

Experts publish first global framework for quantifying postbiotics

AUG 7, 2025
$2.6M NIH grant to fund new microbiome sciences training program at Penn State
Pharma & Human Health

$2.6M NIH grant to fund new microbiome sciences training program at Penn State

JUL 24, 2025
BioGaia launches subsidiary company dedicated to advancing microbiome research and innovation
Finance

BioGaia launches subsidiary company dedicated to advancing microbiome research and innovation

JUL 21, 2025
New UK research network to unlock gut, immune and brain health links
Gut-Brain Axis

New UK research network to unlock gut, immune and brain health links

JUL 9, 2025
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg®
Finance

MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg®

JUL 2, 2025
Towards a diagnostic test: the gut microbiome as a clinical target for screening for colorectal cancer
Gastrointestinal

Towards a diagnostic test: the gut microbiome as a clinical target for screening for colorectal cancer

JUL 2, 2025
Danone further invests in next-generation biotics with acquisition of The Akkermansia Company
Finance

Danone further invests in next-generation biotics with acquisition of The Akkermansia Company

JUN 26, 2025
Bausch Health Partners with YUN
Pharma & Human Health

Bausch Health Partners with YUN

JUN 24, 2025
EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
Editor's Choice

EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum

JUN 23, 2025